Head and neck squamous cell carcinoma (HNSCC) represents the vast majority (i.e., more than 90%) of head and neck tumors. Notably, HNSCC represents the sixth most common cancer worldwide and currently, for this tumor, an incidence of over 600,000 people per year is reported [1,2].
Outcome is age and stage related. In addition, 5-year survival rates superior to 54% for young patients (15–45 years of age) and of 35% for older patients (>75 years of age) have been reported . Notably, despite the massive advances achieved over the last few years in HNSCC therapeutic management, for advanced stages of diease, the mortality rate is still very high.